Royalty Pharma (RPRX) Revenue (2019 - 2026)

Royalty Pharma has disclosed Revenue across 8 years of filings, most recently posting $630.6 million for Q1 2026.

• Revenue for Q1 2026 came in at $630.6 million, up 10.97% year-over-year; the trailing twelve-month figure through Mar 2026 was $2.4 billion (up 7.8% YoY), and the FY2025 annual result was $2.4 billion, up 5.06% from the prior year.
• Revenue came in at $630.6 million for Q1 2026 at Royalty Pharma, up from $622.0 million in the prior quarter.
• In the past five years, Revenue ranged from a high of $684.0 million in Q1 2023 to a low of $536.0 million in Q2 2022.
• The 5-year median for Revenue is $568.2 million (2025), against an average of $580.2 million.
• Across the five-year window, Revenue grew 21.69% in 2023 and dropped 16.96% in 2024, its largest moves.
• Royalty Pharma's Revenue stood at $565.7 million in 2022, then increased by 5.36% to $596.1 million in 2023, then declined by 0.41% to $593.6 million in 2024, then climbed by 4.78% to $622.0 million in 2025, then grew by 1.38% to $630.6 million in 2026.
• The last three Revenue figures came in at $630.6 million (Q1 2026), $622.0 million (Q4 2025), and $609.3 million (Q3 2025), per Business Quant data.